In the BioHarmony Drug Report Database

"Preview" Icon

Indacaterol

Arcapta Neohaler, Hirobriz Breezhaler, Onbrez Breezhaler, Oslif Breezhaler (indacaterol) is a small molecule pharmaceutical. Indacaterol was first approved as Arcapta Neohaler on 2009-11-29. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against beta-2 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor. Hirobriz breezhaler, onbrez breezhaler, oslif breezhaler’s patents are valid until 2028-10-11 (FDA).

 

Trade Name

 

Hirobriz Breezhaler, Onbrez Breezhaler, Oslif Breezhaler
 

Common Name

 

indacaterol
 

ChEMBL ID

 

CHEMBL1095777
 

Indication

 

chronic bronchitis, chronic obstructive pulmonary disease, pulmonary emphysema
 

Drug Class

 

Bronchodilators (phenethylamine derivatives)

Image (chem structure or protein)

Indacaterol structure rendering